Independent and not affiliated with the FDA, MHRA, ISPE, PDA, or any agency. Get the appgoutham@madhadi.com
madhadi.comData Integrity & GxP Quality
Browse all topics → Articles Templates & Procedures Learning paths GlossaryScenariosToolsRegulatory ReferencesLearning PathsTopics About Start here
Checklist Plug-and-play starting point Audits & Inspection

Checklist: FDA 483 Response Pre-Submission Quality Review

A plug-and-play pre-submission checklist for an FDA Form 483 or Warning Letter response: timing, per-observation root cause and CAPA depth, scope, effectiveness checks, data-integrity handling, commitment-register reconciliation, and submission mechanics, with pass/fail items and signoff.

Document type: Checklist

Read and copy the template below into your own quality system. It is a generic starting point for your own internal use, provided as is, with no warranty; see the Terms and License. Adopting it does not by itself create compliance.

This is a ready-to-use checklist to run on an FDA Form 483 or Warning Letter response before it is submitted. It is the quality gate that catches the recurring reasons responses fail: a restated-observation root cause, a training-only CAPA, no scope assessment, no effectiveness check, or a data-integrity finding treated as a documentation slip. Work each item, mark Pass / Fail / NA, and do not submit while any item is Fail. Replace every <<FILL: ...>> placeholder. This content is educational and general, not legal advice; use it with your own regulatory and legal review.

FieldEntry
Inspection / 483 reference<<FILL>>
483 issue date<<FILL>>
15-business-day response date<<FILL>>
Response typeFull / Interim
Reviewer<<FILL>>
Review date<<FILL>>

Section A: Timing and mechanics

#ItemPass / Fail / NANotes
A1The response (or an interim response) will be submitted within 15 business days of the 483 issue date
A2If interim, it acknowledges every observation, states immediate containment, and commits to dated completion of the rest
A3The response is addressed to the correct office and named contact, through the specified channel
A4A dated, complete archive copy will be retained in the master response file

Section B: Structure and per-observation completeness

#Item (repeat per observation)Pass / Fail / NANotes
B1Every numbered observation is addressed separately, in FDA’s order, using the agency’s observation text as the heading
B2Each observation response opens by acknowledging the finding, not by arguing it
B3Each observation has a root cause, corrective action, scope/preventive assessment, effectiveness check, and evidence
B4Attachments are numbered and referenced inline; one observation’s evidence is not buried in another’s

Section C: Root cause depth

#Item (per observation)Pass / Fail / NANotes
C1The root cause names a system, procedure, or design element, not an individual’s care (“lack of training”/“human error” are not the stopping point)
C2The root cause is not merely a restatement of the observation
C3A structured method was used to real depth (several “whys” or a fishbone), and alternatives considered were ruled out with evidence
C4A second reader could reach the same cause from the evidence provided

Section D: Corrective and preventive action

#Item (per observation)Pass / Fail / NANotes
D1Each action is specific, with a named role owner and a specific calendar date (not “within X months”)
D2The CAPA is not training-only; there is a genuine action that removes the cause, not just retraining
D3Correction, corrective action, and preventive action are distinguished; at least one preventive action addresses the mechanism
D4Scope: the response evidences whether the same cause exists in other systems, processes, or sites
D5Each observation has an effectiveness check with a date and acceptance criteria
D6Timelines are realistic; no aggressive date is committed that is expected to slip; long/system-replacement work has credible interim controls

Section E: Data integrity findings (if any)

#ItemPass / Fail / NANotes
E1The finding is characterized as a systemic control gap or intentional falsification, with a documented conclusion
E2The breach is scoped: a retrospective review assessed whether it extends beyond the systems and period the investigator identified
E3Reliability of the affected data is addressed, especially where it supports a submission or released product
E4Legal counsel has reviewed; for serious cases a qualified third-party assessment is proposed rather than awaited

Section F: Commitment reconciliation and ownership

#ItemPass / Fail / NANotes
F1Every dated commitment in the response is on the commitment register with owner, date, status, and evidence record
F2Every commitment has a matching CAPA or change-control record in the quality system with the same date
F3The response reads as the company’s own voice; the people who do the work can explain in their own words what changed and why
F4The quality unit will sign; the response is not signed by regulatory affairs alone

Overall disposition

FieldEntry
Any item Fail?Yes / No
DispositionReady to submit / Return for rework
Reviewer signoff (name, date)<<FILL>>
Quality signatory signoff (name, date)<<FILL>>

Do not submit while any item is Fail. Record the rework and re-review before disposition.

References

Federal Food, Drug, and Cosmetic Act, section 704. 21 CFR 211.22, 211.192. FDA draft guidance, Responding to FDA Form 483 Observations at the Conclusion of a Drug CGMP Inspection (draft, March 2026; confirm status). FDA guidance, Data Integrity and Compliance With Drug CGMP: Questions and Answers (2018).

Filled specimen

The following shows selected items completed for one observation, so you can see the level of scrutiny expected. Illustrative content; replace with your own.

#ItemResultNotes
C1Root cause names a system, not a personPassCause is a change-control gap: testing sequence changed without updating the disposition SOP
C2Not a restatementPassDoes not say “review was not adequate”; names why the hold point was missing
D2Not training-onlyFail (initial)Draft said “retrain the reviewer”; reworked to close the change-control gap and add the missing hold point
D4Scope assessedPassAll disposition SOPs checked for the same missing-dependency pattern
D5Effectiveness check presentPassSample 30 dispositions at 90 days; zero released before all dependent results final
F2Matched in quality systemPassCC-1051 opened with the same 2026-06-15 date

In this example the checklist caught a training-only CAPA (D2) before submission, sent it back, and the reworked response fixed the actual change-control gap. That single catch is the difference between a response that closes and one that escalates.

Common inspection findings this checklist prevents

  • A restated-observation root cause reaching the agency.
  • A training-only CAPA with no systemic fix.
  • No scope assessment, so the next inspection finds the same gap elsewhere.
  • Commitments in the letter with no matching quality-system record.
  • A data-integrity finding answered without the systemic-versus-intentional conclusion.

How to adapt this checklist

  1. Repeat Sections B, C, and D per observation; a three-observation 483 runs those sections three times.
  2. Point the references at the current guidance status before use.
  3. Add house-specific items your quality unit requires (for example a specific legal-review signoff for submission-affecting findings).
  4. Keep the completed checklist as a record in the master response file.
Use madhadi.com as an app Full screen, works offline, one tap from your home screen.